IL23A and inflammatory bowel disease: While previous studies assessing the expression of IL-17 and IL-23 in IBD patients have classified patients according to “disease severity”, they have primarily relied on disease activity scores that have been symptom based at a point in time; however, patients may have severe disease, warranting aggressive therapies even if their disease presentation is not severe.